Lintuzumab
- Generic Name
- Lintuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 166089-32-3
- Unique Ingredient Identifier
- V00Y10W60W
- Background
Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00502112
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸St.Vincent's Comprehensive Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT00283114
- Locations
- 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸University of Massachusetts Medical Center, Worcester, Massachusetts, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath